{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:23:50Z","timestamp":1792700630184,"version":"4.5.0"},"reference-count":34,"publisher":"Walter de Gruyter GmbH","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2020-0122_s_999\">\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Anti-mitochondrial autoantibodies (AMA) detected by indirect immunofluorescence (IIF) on rodent tissues are the diagnostic marker of primary biliary cholangitis (PBC). However, up to 15% of patients with PBC are AMA-negative by IIF. In the effort to close the serological gap and improve the diagnostic sensitivity of PBC testing, recently, novel autoantibodies specific for PBC, such as kelch-like 12 (KLHL12, KLp epitope) and hexokinase 1 (HK1) have been described. In this study, we evaluated the autoantibody profile in a large cohort of PBC patients and in patients with other liver disease, including anti-HK1 and anti-KLp autoantibodies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2020-0122_s_998\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Sera of 194 PBC patients (126 AMA-IIF-positive and 68 AMA-IIF-negative) and 138 disease controls were tested for a panel of PBC-specific antibodies (MIT3, sp100, gp210, HK1, KLp) using a new automated particle-based multi-analyte technology (PMAT) assay on the Aptiva instrument (Inova).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2020-0122_s_997\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Selecting a cutoff yielding a specificity of &gt;95% for all the markers, the sensitivity for anti-MIT3, anti-sp100, anti-gp210, anti-HK1 and anti-KLp in the PBC AMA-IIF-negative cohort was 20.6%, 16.2%, 23.5%, 22.0%, 17.6 and 13.2%, respectively. Six out of the 68 (8.8%) AMA-IIF negative sera were positive for anti-HK1 or anti-KLp alone. Using these new markers in addition to anti-MIT3, anti-sp100 and anti-gp210, the overall sensitivity in this cohort of AMA-IIF-negative patients increased from 53% to 61.8%, reducing the serological gap in AMA-negative PBC patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2020-0122_s_996\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>PBC antibody profiling, made possible by the new Aptiva-PMAT technology, allows recognition of a higher number of AMA-negative PBC patients than conventional immunoassays and may represent a useful tool to evaluate the prognostic significance of autoantibody association in PBC patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2020-0122","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T13:13:28Z","timestamp":1587129208000},"page":"1499-1507","source":"Crossref","is-referenced-by-count":26,"title":["Evaluation of a novel extended automated particle-based multi-analyte assay for the detection of autoantibodies in the diagnosis of primary biliary cholangitis"],"prefix":"10.1515","volume":"58","author":[{"given":"Danilo","family":"Villalta","sequence":"first","affiliation":[{"name":"Immunologia e Allergologia , Ospedale S. Maria degli Angeli , Pordenone , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Seaman","sequence":"additional","affiliation":[{"name":"Research and Development, Inova Diagnostics , San Diego, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marychel","family":"Tiongson","sequence":"additional","affiliation":[{"name":"Research and Development, Inova Diagnostics , San Diego, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Warren","sequence":"additional","affiliation":[{"name":"Research and Development, Inova Diagnostics , San Diego, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Bentow","sequence":"additional","affiliation":[{"name":"Research and Development, Inova Diagnostics , San Diego, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Bizzaro","sequence":"additional","affiliation":[{"name":"Laboratorio di Patologia Clinica, Ospedale S. Antonio, Tolmezzo (UD) , via M.L. King 25 , 30027 San Don\u00e0 di Piave (Venice) , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Alessio","sequence":"additional","affiliation":[{"name":"Dipartimento di Patologia Clinica, Laboratorio Analisi , AO Papa Giovanni XXIII , Bergamo , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7447-9136","authenticated-orcid":false,"given":"Brunetta","family":"Porcelli","sequence":"additional","affiliation":[{"name":"Dipartimento di Biotecnologie Mediche , Universit\u00e0 di Siena, Policlinico Le Scotte , Siena , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary L.","family":"Norman","sequence":"additional","affiliation":[{"name":"Research and Development, Inova Diagnostics , San Diego, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mahler","sequence":"additional","affiliation":[{"name":"Research and Development, Inova Diagnostics , San Diego, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,4,10]]},"reference":[{"key":"2023033110401816736_j_cclm-2020-0122_ref_001","doi-asserted-by":"crossref","unstructured":"Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005;353:1261\u201373.","DOI":"10.1056\/NEJMra043898"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_002","doi-asserted-by":"crossref","unstructured":"Walker JG, Doniach D, Roitt IM, Sherlock S. Serological tests in diagnosis of primary biliary cirrhosis. Lancet 1965;1:827\u201331.","DOI":"10.1016\/S0140-6736(65)91372-3"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_003","doi-asserted-by":"crossref","unstructured":"Achenza MI, Meda F, Brunetta E, Selmi C. Serum autoantibodies for the diagnosis and management of autoimmune liver diseases. Exp Rev Gastroenterol Hepatol 2012;6:717\u201329.","DOI":"10.1586\/egh.12.58"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_004","doi-asserted-by":"crossref","unstructured":"Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology 2009;50:201\u2013308.","DOI":"10.1002\/hep.22906"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_005","unstructured":"EASL. Clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009;13:441\u20134."},{"key":"2023033110401816736_j_cclm-2020-0122_ref_006","doi-asserted-by":"crossref","unstructured":"EASL. Clinical practice guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017;67:145\u201372.","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_007","doi-asserted-by":"crossref","unstructured":"Muratori P, Muratori L, Gershwin ME, Czaja AJ, Pappas G, MacCariello S, et al. True antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assay, or both? Clin Exp Immunol 2004;135:154\u20138.","DOI":"10.1111\/j.1365-2249.2004.02332.x"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_008","doi-asserted-by":"crossref","unstructured":"Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 2005;25:298\u2013310.","DOI":"10.1055\/s-2005-916321"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_009","doi-asserted-by":"crossref","unstructured":"Muratori P, Muratori. Autoantibodies in antimitochondrial antibody negative primary biliary cholangitis. Clin Res Hepatol Gastroenterol 2017;41:e47.","DOI":"10.1016\/j.clinre.2017.04.016"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_010","doi-asserted-by":"crossref","unstructured":"Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70kd mitochondrial antigen recognized in primay biliary cirrhosis. J Immunol 1987;138:3525\u201331.","DOI":"10.4049\/jimmunol.138.10.3525"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_011","doi-asserted-by":"crossref","unstructured":"Leung PS, Choi J, Yang G, Woo E, Kenny TP, Gershwin ME. A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis. Expert Rev Mol Diagn 2016;16:697\u2013705.","DOI":"10.1586\/14737159.2016.1164038"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_012","doi-asserted-by":"crossref","unstructured":"Bassendine MF, Jones DE, Yeaman SJ. Biochemistry and autoimmune response to the 2-oxoacid dehydrogenase complexes in primary biliary cirrhosis. Semin Liver Dis 1997;17:49\u201360.","DOI":"10.1055\/s-2007-1007182"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_013","doi-asserted-by":"crossref","unstructured":"Miyakawa H, Tanaka A, Kikuchi K, Matsushita M, Kitazawa E, Kawaguchi N, et al. Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. Hepatology 2001;34:243\u20138.","DOI":"10.1053\/jhep.2001.26514"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_014","doi-asserted-by":"crossref","unstructured":"Gabeta S, Norman GL, Liaskos C, Papamichalis PA, Zografos T, Garagounis A, et al. Diagnostic relevance and clinical significance of the new enhanced performance M3 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J Clin Immunol 2007;27:378\u201387.","DOI":"10.1007\/s10875-007-9092-0"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_015","doi-asserted-by":"crossref","unstructured":"D\u00e4hnrich C, Pares A, Caballeria I, Rosemann A, Schlumberger W, Probst C, et al. New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies. Clin Chem 2009;55:978\u201385.","DOI":"10.1373\/clinchem.2008.118299"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_016","doi-asserted-by":"crossref","unstructured":"Leung PS, Coppel RI, Ansari A, Munoz S, Gershwin ME. Antimitochondrial antibodies in primary biliary cirrhosis. Semin Liver Dis 1997;17:61\u20139.","DOI":"10.1055\/s-2007-1007183"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_017","doi-asserted-by":"crossref","unstructured":"Bizzaro N, Covini G, Rosina F, Muratori P, Tonutti E, Villalta D, et al. Overcoming a \u201cprobable\u201d diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: a study of 100 sera and review of the literature. Clin Rev Allergy Immunol 2012;42:288\u201397.","DOI":"10.1007\/s12016-010-8234-y"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_018","doi-asserted-by":"crossref","unstructured":"Villalta D, Sorrentino MC, Girolami E, Tampoia M, Alessio MG, Brusca I, et al. Autoantibody profiling of patients with primary biliary cirrhosis using a multiplexed line-blot assay. Clin Chim Acta 2015;438:135\u20138.","DOI":"10.1016\/j.cca.2014.08.024"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_019","doi-asserted-by":"crossref","unstructured":"Zhang Q, Liu Z, Wu S, Duan W, Chen S, Ou X, et al. Meta-analysis of antinuclear antibodies in the diagnosis of antimitochondrial antibody-negative primary biliary cholangitis. Gastroenterol Res Pract 2019;2019:8959103.  Doi: 10.1155\/2019\/8959103. eCollection 2019.","DOI":"10.1155\/2019\/8959103"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_020","doi-asserted-by":"crossref","unstructured":"Hu CJ, Song G, Huang W, Liu GZ, Deng CW, Zeng HP, et al. Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays. Mol Cell Proteomics 2012;11:669\u201380.","DOI":"10.1074\/mcp.M111.015529"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_021","doi-asserted-by":"crossref","unstructured":"Norman GL, Yang CY, Ostendorff HP, Shums Z, Lim MJ, Wang J, et al. Anti-kelch-like and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver Int 2015;35:642\u201351.","DOI":"10.1111\/liv.12690"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_022","doi-asserted-by":"crossref","unstructured":"Bombaci M, Pesce E, Torri A, Carpi D, Crosti M, Cordiglieri C, et al. Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms. Liver Int 2019;39:2124\u201335.","DOI":"10.1111\/liv.14128"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_023","unstructured":"Norman GL, Shums Z, Encabo S, Milo J, Mahler M, Swain MG, et al. Examination of Canadian primary biliary cholangitis (PBC) patients by conventional and novel-PBC-specific biomarkers. Hepatol 2016;64 (suppl 1):383"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_024","doi-asserted-by":"crossref","unstructured":"Hennes EM, Zeniya M, Czaja AJ, Par\u00e9s A, Dalekos JN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169\u201376.","DOI":"10.1002\/hep.22322"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_025","doi-asserted-by":"crossref","unstructured":"Yiman KK, Bowlus CI. Diagnosis and classification of primary sclerosing cholangitis. Autoimmune Rev 2014;13:445\u201350.","DOI":"10.1016\/j.autrev.2014.01.040"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_026","doi-asserted-by":"crossref","unstructured":"Richards M, Garcia-De La Torre I, Gonzalez-Bello YC, Vazquez-Del MM, Andrade-Ortega L, Medrano-Ramirez G, et al. Autoantibodies to Mi-2 alpha and Mi-2 beta in patients with idiopathic inflammatory myopathy. Rheumatology 2019;76:867\u20138.","DOI":"10.1093\/rheumatology\/kez092"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_027","doi-asserted-by":"crossref","unstructured":"Milkiewicz M, Caballeria I, Smyk DS, Milkiewicz P. Predicting and preventing autoimmunity: the case of anti-mitochondrial antibodies. Auto Immun Highlights 2012;3:105\u201312.","DOI":"10.1007\/s13317-012-0038-z"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_028","doi-asserted-by":"crossref","unstructured":"Liu H, Norman GL, Shums Z, Worman HJ, Krawitt EL, Bizzaro N, et al. PBC screen: an IgG\/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific from primary biliary cirrhosis. J Autoimmun 2010;35:346\u20132.","DOI":"10.1016\/j.jaut.2010.09.005"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_029","doi-asserted-by":"crossref","unstructured":"Robey RB, Hay N. Mitochondrial hexokinases: guardians of the mitochondria. Cell Cycle 2005;4:654\u20138.","DOI":"10.4161\/cc.4.5.1678"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_030","doi-asserted-by":"crossref","unstructured":"Gupta VA, Beggs AH. Kelch proteins: emerging roles in skeletal muscle development and diseases. Skeletal Muscle 2014;4:11\u20132.","DOI":"10.1186\/2044-5040-4-11"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_031","doi-asserted-by":"crossref","unstructured":"Dhanoa BS, Cogliati T, Satish AG, Bruford EA, Friedman JS. Update on the Kelch-like (KLHL) gene family. Hum Genomics 2013;7:13.","DOI":"10.1186\/1479-7364-7-13"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_032","doi-asserted-by":"crossref","unstructured":"Hu SL, Zhao FR, Hu Q, Chen WX. Meta-analysis assessment of gp210 and Sp100 for the diagnosis of primary biliary cirrhosis. PLoS One 2014;9:e101916.","DOI":"10.1371\/journal.pone.0101916"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_033","doi-asserted-by":"crossref","unstructured":"Norman GL, Reig A, Vi\u00f1as O, Mahler M, Wunsch E, Milkiewicz P, et al. The prevalence of anti-hexokinase-1 and anti-kelch-like 12 peptide antibodies in patients with primary biliary cholangitis is similar in Europe and North America: a large international, multi-center study. Front Immunol 2019;10:662.","DOI":"10.3389\/fimmu.2019.00662"},{"key":"2023033110401816736_j_cclm-2020-0122_ref_034","doi-asserted-by":"crossref","unstructured":"Reig A, Garcia M, Shums Z, Milo J, Encabo S, Bentow C, et al.  The novel hexokinase (HK-1) antibodies are useful for diagnosis and associated with bad prognosis in primary biliary cholangitis. J Hepatol 2017;(Suppl 1):S355\u20136.","DOI":"10.1016\/S0168-8278(17)31049-8"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/cclm\/58\/9\/article-p1499.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2020-0122\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2020-0122\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T12:44:40Z","timestamp":1680266680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2020-0122\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,10]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,7,15]]},"published-print":{"date-parts":[[2020,8,27]]}},"alternative-id":["10.1515\/cclm-2020-0122"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2020-0122","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,10]]}}}